Prostate cancer is one of the most common malignant tumors of the male reproductive system, mostly occurring above the age of 50, and the incidence increases with age. There are significant geographical and racial differences in the incidence of prostate cancer, with high incidence in Western countries such as Europe and the United States, and a much lower incidence of prostate cancer in Asia than in Europe and the United States, but in recent years. From a year-by-year increasing trend.
Prostate cancer, a malignant tumor of the prostate gland, has various treatment principles: first, non-surgical treatment, when the tumor stage is early or the patient is older, the process of prostate cancer needs to be monitored, and further treatment is required when tumor progression and clinical symptoms occur,
Second, when the lesion is located within the prostate envelope, T1 and T2, radical prostatectomy is required
Second, when the lesion is within the prostate envelope, T1 and T2, radical prostatectomy is required.
Thirdly, when prostate cancer reaches T3 and T4 stages, surgical debulking and other endocrine treatments such as anti-androgen therapy are feasible.
Postoperative prostate cancer requires regular PSA testing, rectal examinations and PSA after debulking treatment, prostate ultrasound, blood tests, testosterone levels, liver function, and other regular reviews to determine if there is recurrence. In summary, prostate cancer cannot be completely cured, each stage needs to be handled differently, but all require regular review and further treatment if there is a recurrence.